By Fineline Cube Otsuka Pharmaceutical Co., Ltd. (OTCMKTS: OTSKY) announced today that China’s National Medical Products Administration (NMPA) has granted marketing approval for Voyxact (sibeprenlimab) for reducing proteinuria in adult patients with primary immunoglobulin A nephropathy (IgA nephropathy) who are at risk of disease progression.
Regulatory Milestone
| Component | Detail |
|---|---|
| Drug Name | Voyxact (sibeprenlimab) |
| Developer | Otsuka Pharmaceutical Co., Ltd. (OTCMKTS: OTSKY) |
| Approval Authority | National Medical Products Administration (NMPA), China |
| Indication | Reduction of proteinuria in adult patients with primary IgA nephropathy at risk of disease progression |
| Basis for Approval | Phase III VISIONARY study results |
| Mechanism of Action | Monoclonal antibody targeting APRIL to reduce IgA and Gd-IgA1 levels |
Clinical Trial Results – VISIONARY Study
Global Population (n=510)
| Endpoint | Sibeprenlimab vs. Placebo |
|---|---|
| Study Design | Phase III, double-blind, placebo-controlled |
| Geographic Scope | 31 countries across 5 continents |
| Chinese Patients | 102 (from mainland China) |
| 9-Month UPCR-24h Reduction | 51.2% (p<0.001) |
| 12-Month UPCR-24h Reduction | 54.3% (p<0.001) |
Chinese Subgroup Analysis (n=102)
- 9-Month UPCR-24h Reduction: 61.9% compared with placebo
- Therapeutic Efficacy: Demonstrated excellent response in Chinese population
- Consistency: Results consistent with global population with potentially enhanced effect
Disease Context & Market Opportunity
- IgA Nephropathy Prevalence: Most common primary glomerulonephritis globally, affecting approximately 40-50 per 100,000 people
- Disease Progression: Up to 40% of patients progress to end-stage kidney disease within 20 years
- Treatment Gap: Limited approved therapies specifically targeting the underlying pathophysiology
- Proteinuria Significance: Key predictor of disease progression; reduction correlates with improved long-term renal outcomes
Strategic Implications
- First-in-Class Potential: Sibeprenlimab represents a novel mechanism targeting the APRIL pathway in IgA nephropathy
- China Market Access: NMPA approval provides access to world’s largest IgA nephropathy patient population
- Global Development: Part of broader international regulatory strategy with potential approvals in other major markets
- Commercial Infrastructure: Leverages Otsuka’s established nephrology commercial capabilities in Asia
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical development, market opportunities, and commercial expectations. Actual results may differ due to risks including post-marketing surveillance requirements, competitive dynamics, reimbursement challenges, and market adoption patterns.-Fineline Info & Tech